Journal Publications from PrEPVacc

Journal publications from the PrEPVacc study

  1. Kusemererwa S, Kansiime S, Mutonyi G, Namirembe A, Katana S, Kitonsa J, Kakande A, Okello JM, Kaleebu P, Ruzagira E. Predictors of oral pre-exposure prophylaxis (PrEP) uptake among individuals in an HIV vaccine preparedness cohort in Masaka, Uganda. Medicine (Baltimore). 2021 Nov 5;100(44):e27719.

  2. Kabarambi A, Kansiime S, Kusemererwa S, Kitonsa J, Kaleebu P, Ruzagira E; PrEPVacc Study Group. Predictors of Loss to Follow-Up in an HIV Vaccine Preparedness Study in Masaka, Uganda. Int J Environ Res Public Health. 2022 May 24;19(11):6377.

  3. Faini D, Munseri P, Sandstrom E, Hanson C, Bakari M. Awareness, Willingness and Use of HIV Pre-Exposure Prophylaxis Among Female Sex Workers Living in Dar-es-Salaam, Tanzania. AIDS Behav. 2022 Jul 15.

  4. Nakamanya S, Kawuma R, Kibuuka D, Kusemererwa S, McCormack S, Ruzagira E, Seeley J; PrEPVacc Study Group. Assessing acceptability of pre-exposure prophylaxis (PrEP) among participants in an HIV vaccine preparedness study in southwestern Uganda. PLoS One. 2022 Jul 29;17(7):e0271104. DOI: 10.1371/journal.pone.0271104 PMID: 35905052; PMCID: PMC9337655.

    Read a PrEPVacc Q&A with the Investigator Sarah Nakamanya about this publication

  5. Faini D, Msafiri F, Munseri P, Bakari M, Lyamuya E, Sandström E, Biberfeld G, Nilsson C, Hanson C, Aboud S. The prevalence, incidence, and risk factors for HIV among female sex workers - a cohort being prepared for a phase IIb HIV vaccine trial in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr. 2022 Sep 20.

  6. Ben Gombe, Claire Streatfield, Lorna Leal, Solomon Opio, Sarah Joseph, Jonathan Weber, Jonathan Hare, Pontiano Kaleebu, Jennifer Serwanga. Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial. PLOS ONE 17(11): e0275927 (3 November 2022).

  7. Chimukuche, R.S., Kawuma, R., Mahapa, N. et al. Examining oral pre-exposure prophylaxis (PrEP) literacy among participants in an HIV vaccine trial preparedness cohort study. BMC Health Serv Res 22, 1336 (2022).

    Read a PrEPVacc Q&A with the Investigator Samanthia Chimukuche about this publication

  8. Sheila Kansiime, Christian Holm Hansen, Richard Hayes, Eugene Ruzagira, on behalf of the PrEPVacc Study Team. Developing HIV risk prediction tools in four African settings. Tropical Medicine & International Health. (First published: 27 July 2023)

  9. Deborah Donnell, Sheila Kansiime , David V. Glidden , Alex Luedtke , Peter B. Gilbert , Fei Gao and Holly Janes. Study design approaches for future active-controlled HIV prevention trials. Statistical Communications in Infectious Diseases (January 22, 2024)

  10. Oral abstract presentation at AIDS 2024: OAC08 Final vaccine efficacy results from PrEPVacc: A phase IIb HIV prophylactic vaccine trial of two active regimens each compared to placebo Eugene Ruzagira | 23 July 2024 | 16:30-17:30 | Hall B0a/Channel 4 (https://programme.aids2024.org/Programme/Session/207)

    *Powerpoint slides presented at AIDS 2024 here*

List last updated 13 November 2024